Glaxo took over Wellcome to boost profits at risk from the Zantac patent expiration. But its R&D managers used the tumult and pain caused by the deal to revitalize an organization which had grown complacent and was ill-equipped to exploit the new technologies which were industrializing drug discovery. Productivity is way up--with no increase in budget. But has Glaxo Wellcome really accomplished its mission or is a continuing series of cost-squeezing mergers still inevitable?
By Jeffrey Dvorin
Shortly after its hostile $14 billion takeover of Wellcome, Glaxo Wellcome PLC (GW)'s discovery chief, Allan Baxter (then head...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.
Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.
